Literature DB >> 21444701

Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece.

Michael Arabatzis1, Manousos Kambouris, Miltiades Kyprianou, Aikaterini Chrysaki, Maria Foustoukou, Maria Kanellopoulou, Lydia Kondyli, Georgia Kouppari, Chrysa Koutsia-Karouzou, Evangelia Lebessi, Anastasia Pangalis, Efthimia Petinaki, Ageliki Stathi, Eleftheria Trikka-Graphakos, Erriketi Vartzioti, Aliki Vogiatzi, Timoleon-Achilleas Vyzantiadis, Loukia Zerva, Aristea Velegraki.   

Abstract

In this study, the first such study in Greece, we used polyphasic identification combined with antifungal susceptibility study to analyze Aspergillus clinical isolates comprising 102 common and rare members of sections Fumigati, Flavi, Terrei, Nidulantes, Nigri, Circumdati, Versicolores, and Usti. High amphotericin B MICs (>2 μg/ml) were found for 17.6% of strains. Itraconazole, posaconazole, and voriconazole MICs of >4 μg/ml were shown in 1%, 5%, and 0% of the isolates, respectively. Anidulafungin, micafungin, and caspofungin minimum effective concentrations (MECs) of ≥2 μg/ml were correspondingly recorded for 4%, 9%, and 33%, respectively, of the strains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444701      PMCID: PMC3101447          DOI: 10.1128/AAC.01491-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Aspergillosis. Pathogenesis, clinical manifestations, and therapy.

Authors:  Kieren A Marr; Thomas Patterson; David Denning
Journal:  Infect Dis Clin North Am       Date:  2002-12       Impact factor: 5.982

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.

Authors:  Jesús Guinea; Sandra Recio; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

4.  Four new species of Emericella from the Mediterranean region of Europe.

Authors:  Polona Zalar; Jens C Frisvad; Nina Gunde-Cimerman; János Varga; Robert A Samson
Journal:  Mycologia       Date:  2008 Sep-Oct       Impact factor: 2.696

5.  Phylogenetic analysis of Aspergillus species using DNA sequences from four loci.

Authors:  Stephen W Peterson
Journal:  Mycologia       Date:  2008 Mar-Apr       Impact factor: 2.696

6.  Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2010-12-01       Impact factor: 5.948

7.  Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus.

Authors:  S Arunmozhi Balajee; Jennifer L Gribskov; Edward Hanley; David Nickle; Kieren A Marr
Journal:  Eukaryot Cell       Date:  2005-03

8.  Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

9.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

10.  Aspergillus species identification in the clinical setting.

Authors:  S A Balajee; J Houbraken; P E Verweij; S-B Hong; T Yaghuchi; J Varga; R A Samson
Journal:  Stud Mycol       Date:  2007       Impact factor: 16.097

View more
  11 in total

Review 1.  Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification.

Authors:  R Araujo; M Oliveira; A Amorim; B Sampaio-Maia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-18       Impact factor: 3.267

2.  Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan.

Authors:  Masato Tashiro; Koichi Izumikawa; Asuka Minematsu; Katsuji Hirano; Naoki Iwanaga; Shotaro Ide; Tomo Mihara; Naoki Hosogaya; Takahiro Takazono; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Tomoya Nishino; Misuzu Tsukamoto; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Akira Yasuoka; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

3.  Multilocus Phylogeny and Antifungal Susceptibility of Aspergillus Section Circumdati from Clinical Samples and Description of A. pseudosclerotiorum sp. nov.

Authors:  J P Z Siqueira; D A Sutton; J Gené; D García; N Wiederhold; S W Peterson; J Guarro
Journal:  J Clin Microbiol       Date:  2017-01-04       Impact factor: 5.948

4.  Aspergillus section Nidulantes (formerly Emericella): Polyphasic taxonomy, chemistry and biology.

Authors:  A J Chen; J C Frisvad; B D Sun; J Varga; S Kocsubé; J Dijksterhuis; D H Kim; S-B Hong; J Houbraken; R A Samson
Journal:  Stud Mycol       Date:  2016-10-19       Impact factor: 16.097

5.  Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus.

Authors:  Masato Tashiro; Koichi Izumikawa; Katsuji Hirano; Shotaro Ide; Tomo Mihara; Naoki Hosogaya; Takahiro Takazono; Yoshitomo Morinaga; Shigeki Nakamura; Shintaro Kurihara; Yoshifumi Imamura; Taiga Miyazaki; Tomoya Nishino; Misuzu Tsukamoto; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Akira Yasuoka; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

Review 6.  Antifungal susceptibility profile of cryptic species of Aspergillus.

Authors:  Ana Alastruey-Izquierdo; Laura Alcazar-Fuoli; Manuel Cuenca-Estrella
Journal:  Mycopathologia       Date:  2014-06-28       Impact factor: 2.574

7.  Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species.

Authors:  Anna Rozaliyani; Asriyani Abdullah; Findra Setianingrum; Wellyzar Sjamsuridzal; Retno Wahyuningsih; Anom Bowolaksono; Ayu Eka Fatril; Robiatul Adawiyah; Mulyati Tugiran; Ridhawati Syam; Heri Wibowo; Chris Kosmidis; David W Denning
Journal:  J Fungi (Basel)       Date:  2022-04-16

8.  β-tubulin paralogue tubC is frequently misidentified as the benA gene in Aspergillus section Nigri taxonomy: primer specificity testing and taxonomic consequences.

Authors:  V Hubka; M Kolarik
Journal:  Persoonia       Date:  2012-10-09       Impact factor: 11.051

9.  Involvement of the opportunistic pathogen Aspergillus tubingensis in osteomyelitis of the maxillary bone: a case report.

Authors:  Erik Bathoorn; Natalia Escobar Salazar; Shahrzad Sepehrkhouy; Martin Meijer; Hans de Cock; Pieter-Jan Haas
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

Review 10.  Triazole Resistance in Aspergillus spp.: A Worldwide Problem?

Authors:  Olga Rivero-Menendez; Ana Alastruey-Izquierdo; Emilia Mellado; Manuel Cuenca-Estrella
Journal:  J Fungi (Basel)       Date:  2016-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.